Shinobi Therapeutics
Ryosuke Gonotsubo is a venture capitalist specialized in university startups based on research results of Kyoto University. With experience in various managerial roles at Kanematsu Corporation and serving as the Representative Director, COO/CFO at Thyas Co. Ltd., Ryosuke currently holds the position of Chief of Staff at Shinobi Therapeutics. Gonotsubo holds an MBA from Carnegie Mellon University's Tepper School of Business and a LLB in Law from Kyoto University.
This person is not in any teams
This person is not in any offices
Shinobi Therapeutics
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.